12 recruiting. 5 Phase 3, 3 Not applicable, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 5 |
| Not applicable | 3 | Recruiting 3 |
| Phase 2 | 3 | Recruiting 3 |
Follow Ming-Yuan Chen: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SBRT Combined With Becotatug Vedotin (MRG003) in EGFR-Positive Metastatic Tumor Patients With Oligometastases Becotatug Vedotin, SBRT, Systemic Therapy/Standard of Care - Oligo-metastatic Cancer | Phase 3 | Recruiting | Ming-Yuan Chen | 200 | 2026-02-06 | 2026-04-02 |
| Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma Neoadjuvant and Adjuvant Becotatug Vedotin, Neoadjuvant and Adjuvant Immunotherapy, Surgery - Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | Ming-Yuan Chen | 430 | 2026-02-06 | 2026-04-13 |
| 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma Cisplatin-based induction chemotherapy, Full course of PD-1 monoclonal antibody, Reduced-dose radiotherapy to CTV2 - Nasopharyngeal Carcinoma | Phase 3 | Recruiting | Ming-Yuan Chen | 346 | 2025-11-20 | 2026-01-09 |
| Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy Full course of PD-1blockades, Cisplatin-based induction chemotherapy, Standard-dose radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 456 | 2025-11-18 | 2026-01-09 |
| Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma Sintilimab + Anlotinib + taxane-based chemotherapy - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 33 | 2025-09-15 | 2026-05-12 |
| Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer Reduced-Target Radiotherapy, Conventional Full-Target Radiotherapy - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Ming-Yuan Chen | 166 | 2025-08-20 | 2025-12-09 |
| Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial Ivonescimab, Nimotuzumab, Irinotecan liposome - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 208 | 2025-06-24 | 2025-09-18 |
| Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas Blood, nasopharyngeal swab and saliva, EBNA1-IgA, VCA-IgA, P85-Ab and EBV DNA, Novel screening biomarkers - Nasopharyngeal Carcinoma (NPC), Screening | Not applicable | Recruiting | Ming-Yuan Chen | 68649 | 2025-01-24 | 2025-03-11 |
| "Xijiang Project" Screening Cohort for NPC EBV antibodies test, EBV DNA test, epidemiological information survey - Nasopharyngeal Carcinoma (NPC), Screening | Recruiting | Ming-Yuan Chen | 1000000 | 2024-11-14 | 2026-09-01 | |
| Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors - Recurrent or Metastatic Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Ming-Yuan Chen | 32 | 2024-07-20 | 2025-01-13 |
| Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Low Dose Radiotherapy, Endoscopic nasopharyngectomy combine Retropharyngeal lymphadenectomy and Double upper neck lymph node dissection - Nasopharyngeal Carcinoma, Surgery | Not applicable | Recruiting | Ming-Yuan Chen | 86 | 2023-11-01 | 2024-11-14 |
| Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma. Surgery combined with Target-reduction intensity-modulated radiotherapy, Surgery combined with Dose-reduction intensity-modulated radiotherapy - Nasopharyngeal Carcinoma | Not applicable | Recruiting | Ming-Yuan Chen | 384 | 2022-11-01 | 2024-07-31 |
Nasopharyngeal Carcinoma (10) · Neoplasm Metastasis (3) · Recurrence (3) · Epstein-Barr Virus Infections (2) · Pathologic Complete Response (2)
Immune Checkpoint Inhibitors (2) · Radiotherapy (2) · Biopsy (1) · Blood Specimen Collection (1) · Neoadjuvant Therapy (1) · Radiotherapy, Adjuvant (1) · Restraint, Physical (1) · S 1 (combination) (1) · Standard of Care (1) · Surgical Procedures, Operative (1) · anlotinib (1) · irinotecan sucrosofate (1) · nimotuzumab (1) · sintilimab (1)
China (12)
Mingyuan Chen (1)